CDKN2A and cancer: Negative p16 expression was observed among a higher proportion of benign tumors (75.0%) as compared to malignant (31.0%) and intermediate (37.5%) while positive p16 expression was observed among a higher proportion of malignant tumors (66.7%) as compared to benign (20.0%) and intermediate (50.0%) while focal positive expression was observed in a higher proportion of Intermediate tumors (12.5%) as compared to benign 5.0%) and malignant cases (2.4%).